BMYBristol-Myers SquibbSigning up patients
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Breast Neoplasms
3Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Worry score3
Score over time
- Stage
- Phase 2/3
- Patients
- 600 (planned)
- Started
- Sep 11, 2025
- Main results expected
- Mar 13, 2028
- Fully finished
- May 15, 2030
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-Free Survival (PFS)
Measured over: Approximately 22 months from first participant randomization in Phase 3
Recommended Phase 3 Dose (RP3D) of BMS-986507
Measured over: Approximately 13 months from first participant randomization in Phase 2
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT06926868 · record last updated 2026-08-10 · checked 2026-11-09 15:42 UTC